RxDoctor Payments Data

Emily Saks, MD

Urogynecology and Reconstructive Pelvic Surgery · Newark, DENPI 1982760872

Payments from drug & device makers

$4,399in general payments, 2019–2025

Across 124 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$999
  • BD$650
  • Coloplast$607
  • Caldera Medical, Inc$512
  • Sumitomo Pharma America, Inc.$308
  • AbbVie$297
  • plus $1K from 10 others

What the payments were for

  • Speaking & faculty fees$65015%
  • Travel & lodging$401%
  • Food & beverage$3,67784%
  • Education$170%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$98,299
Medicare patients
279
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron220$153,923
GemtesaVibegron50$40,907
Trospium Chloride ErTrospium Chloride65$10,333
Mirabegron ErMirabegron15$6,524
PremarinEstrogens, Conjugated12$5,332
Estradiol73$4,489
Trospium Chloride30$1,059
Oxybutynin Chloride ErOxybutynin Chloride23$962
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$504
NitrofurantoinNitrofurantoin Macrocrystal12$329
Cephalexin18$138
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim33$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$222$153,923220 claims
Sumitomo Pharma America, Inc.Gemtesa$308$40,90750 claims
PfizerPremarin$138$5,33212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Newark

Where these figures come from

Is this you, or does something look wrong? →